IMUNON INC (IMNN)

Company Profile

Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 31 full-time employees. The company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The company has two platform technologies: TheraPlas platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies, and the PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer. IMNN-001 works by instructing the body to produce cancer fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, it is conducting preclinical studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus to validate its PLACCINE platform. Its platform technologies are based on the delivery of nucleic acids with synthetic delivery systems that are independent of viral vectors or devices.

Company Info

IMUNON INC

997 Lenox Dr Ste 100

Lawrenceville NEW JERSEY

P: 16098969100

Employees: 31

Website: https://imunon.com/